One-Year Results of Aflibercept in Vascularized Pigment Epithelium Detachment due to Neovascular AMD: A Prospective Study

Purpose To evaluate individualized intravitreal aflibercept regimens for treatment of neovascular age-related macular degeneration (nAMD)-related pigment epithelial detachment (PED). Methods This prospective, multicenter, nonrandomized study included 32 eyes with nAMD-related PED, treated with ranib...

Full description

Saved in:
Bibliographic Details
Published in:European journal of ophthalmology 2017-01, Vol.27 (1), p.74-79
Main Authors: Veritti, Daniele, Sarao, Valentina, Parravano, Mariacristina, Arias, Luis, Varano, Monica, Lanzetta, Paolo
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To evaluate individualized intravitreal aflibercept regimens for treatment of neovascular age-related macular degeneration (nAMD)-related pigment epithelial detachment (PED). Methods This prospective, multicenter, nonrandomized study included 32 eyes with nAMD-related PED, treated with ranibizumab for ≥6 months. All patients received intravitreal aflibercept (2 mg/0.05 mL) at baseline (no loading phase) and subsequently treated pro re nata with monthly follow-up for 12 months. Outcome measures included visual acuity, central retinal thickness (CRT), PED height and area, and neovascular network size. Results At 12 months, aflibercept improved mean best-corrected visual acuity compared with baseline values (p>0.05); 50% of patients displayed complete resolution of intraretinal and/or subretinal fluid. Compared with baseline, significant decreases were observed for mean CRT and PED height (both p
ISSN:1120-6721
1724-6016
DOI:10.5301/ejo.5000880